Aqemia funding news – Paris-based Aqemia Secures $7.4Million in Funding

The grant, part of the "France 2030" initiative will strengthen Aqemia's AI platform, helping it better handle the complex structures of RNA and proteins. Aqemia plans to use the funding to explore RNA and RNA-modifying targets, improve its AI methods, and advance its drug discovery work.

Read also - EcoDataCenter funding news – EcoDataCenter Secures €450 Million in Funding

Aqemia’s AI engine, which has already shown success in epitranscriptomics, is now ready to make progress in targeting RNA, a complex area for therapeutic development.

While focusing on RNA, Aqemia is also making progress in its other drug discovery programs including those targeting proteins. The company aims to develop new small-molecule drugs for RNA, a promising but challenging area in medicine.

RNA is difficult to target due to its complexity, but it plays a key role in gene regulation and diseases like cancer, making it important for drug discovery. Aqemia is using its AI platform to overcome the challenges in developing drugs that target RNA.

Dr. Maximilien Levesque, CEO and Co-Founder of Aqemia, commented on the new funding: “This funding enables us to extend the reach of our technology to previously unexplored targets, opening the door to new classes of treatments. Integrating RNA targeting into our platform reinforces our ambition to transform the invention of new therapeutic solutions for patients. We are grateful for the continued support that allows us to push boundaries and tackle critical medical challenges.”

About AQEMIA

AQEMIA is a cutting-edge pharmatech company with one of the fastest-growing drug discovery pipelines. Their goal is to quickly design innovative drug candidates for important diseases, like cancer.
4o mini